Loading fund…
Loading fund…
| Returns | 1D | 1M | 3M | YTD | 1Y | 3Y | 5Y | MAX |
|---|---|---|---|---|---|---|---|---|
| Total return | ▲ +2.4% | ▲ +7.2% | ▲ +6.3% | ▲ +15.3% | ▲ +30.5% | ▲ +59.3% | ▲ +73.6% | ▲ +364.7% |
| Peer average | ▲ +1.2% | ▲ +4.5% | ▲ +9.5% | ▲ +22.6% | ▲ +30.8% | ▲ +76.1% | ▲ +30.8% | — |
| S&P 500 · VOO | ▼ −0.4% | ▲ +0.9% | ▲ +3.3% | ▲ +13.8% | ▲ +13.3% | ▲ +88.8% | ▲ +81.9% | — |
VanEck Pharmaceutical ETF (PPH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Distribution yield and SEC yield use different methodologies. Payouts may include income, capital gains, or return of capital.
| Ex-date | Pay date | Per share |
|---|---|---|
| 2026-10-01 | 2026-10-06 | $0.36 |
| 2026-07-01 | 2026-07-07 | $0.62 |
| 2026-04-01 | 2026-04-07 | $0.84 |
| 2025-12-29 | 2025-12-31 | $0.31 |
| 2025-10-01 | 2025-10-06 | $0.39 |
| 2025-07-01 | 2025-07-07 | $0.61 |
| 2025-04-01 | 2025-04-04 | $0.52 |
| 2024-12-27 | 2024-12-30 | $0.41 |
| 2024-10-01 | 2024-10-04 | $0.41 |
| 2024-07-01 | 2024-07-05 | $0.36 |
| 2024-04-01 | 2024-04-05 | $0.53 |
| 2023-12-27 | 2023-12-29 | $0.31 |
Estimated annual expense excludes trading costs and assumes constant assets. Fee waivers and fund costs can change.
Historical risk measures describe past behavior and do not predict future returns.
Hear the strategy from the people behind PPH.